Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study

Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study

Abstract Background Prostaglandin analogs are first-line treatments for open-angle glaucoma due to their proven efficacy in reducing intraocular pressure. Despite their topical administration, systemic adverse drug Events (ADEs) have been reported. This study investigates the systemic ADEs associate...

Full description

Saved in:

Bibliographic Details
Main Author:	Kannan Sridharan
Format:	Article
Language:	English
Published:	BMC 2024-12-01
Series:	BMC Ophthalmology
Subjects:	Latanoprost Bimatoprost Travoprost Tafluprost Latanoprostene bunod
Online Access:	https://doi.org/10.1186/s12886-024-03823-w
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Development of a conjunctival contact–type drug delivery device for latanoprost using hyaluronic acid
by: Soomin Lee, et al.
Published: (2025-12-01)

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
by: Jingrong Yang, et al.
Published: (2025-01-01)

Automatic tool for the reconciliation of serious adverse events for pharmacovigilance: design and implementation of Reconciliaid
by: Sara Contu, et al.
Published: (2025-01-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
by: Yalan Tian, et al.
Published: (2025-01-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

Characteristics of glaucoma therapy with prostaglandin analogues nowadays
by: I.B. Alekseev, et al.
Published: (2022-09-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS)
by: Hui Gao, et al.
Published: (2025-01-01)

Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses
by: Kannan Sridharan, et al.
Published: (2025-01-01)

Investigation of the total anticholinergic load of reported anticholinergic drug-related adverse events using the Japanese adverse drug event report database: a retrospective pharmacovigilance study
by: Yusuke Kan, et al.
Published: (2025-01-01)

Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
by: Ximu Sun, et al.
Published: (2025-02-01)

Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data
by: Luyang Su, et al.
Published: (2024-12-01)

Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation
by: Vagiakis I, et al.
Published: (2025-01-01)

Comparison of Bimatoprost 0.03% and Brimonidine 0.2% in Managing Intraocular Pressure Elevation Following Nd:YAG Laser Capsulotomy for Posterior Capsule Opacification
by: Tulika Gupta, et al.
Published: (2024-12-01)

Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Lisi Xu, et al.
Published: (2025-01-01)

Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study
by: Giulia Coco, et al.
Published: (2022-01-01)

Drug-induced heart failure: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Youqi Huang, et al.
Published: (2025-01-01)

High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database
by: Zhishen Ruan, et al.
Published: (2025-01-01)

Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system
by: Yixuan Yang, et al.
Published: (2025-01-01)

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

A Comprehensive 10-Year Nationwide Pharmacovigilance Surveillance on Antibacterial Agents in Korea: Data Mining for Signal Detection of Trends and Seriousness of Adverse Events
by: Seon Hu Mo, et al.
Published: (2025-01-01)

IOP-lowering effect and tolerability of prostaglandin analogues in primary open-angle glaucoma and ocular hypertension as risk factors for glaucoma progression
by: A.V. Belogurova, et al.
Published: (2019-04-01)

Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
by: Yang Hu, et al.
Published: (2020-01-01)

Comparative Analysis of Adverse Drug Reactions Associated with Fluoroquinolones and Other Antibiotics: A Retrospective Pharmacovigilance Study
by: Alshareef H, et al.
Published: (2025-02-01)

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Zhaohui Li, et al.
Published: (2024-11-01)

Pharmacovigilance in veterinary profession
by: Fatih Doğan

Safety and Efficacy of Adding Fixed-Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma
by: Anton Hommer, et al.
Published: (2015-01-01)

Ocular Surface Changes in Prostaglandin Analogue-Treated Patients
by: Wencui Shen, et al.
Published: (2019-01-01)

Adverse Events of Antiepileptic Drugs Using Indonesian Version of Liverpool Adverse Events Profile
by: Astri Budikayanti, et al.
Published: (2018-01-01)

Adverse Reactions from Topical Ophthalmic Anesthetic Abuse
by: Ali Sharifi, et al.
Published: (2022-11-01)

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
by: Wei Mao, et al.
Published: (2025-01-01)

Topical Issues of Value-Focused Engineering Education
by: N. D. Tskhadaya, et al.
Published: (2020-03-01)

The Adverse Impact of Glaucoma on Psychological Function and Daily Physical Activity
by: Wenbin Huang, et al.
Published: (2020-01-01)

Prostaglandin Receptor Signaling in Disease
by: Toshiyuki Matsuoka, et al.
Published: (2007-01-01)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022-01-01)

Acknowledging and addressing real-world challenges to treating immune-related adverse events
by: Bonnie L Bermas, et al.
Published: (2024-07-01)

Complications and adverse events of high-intensity focused ultrasound in its application to gynecological field - a systematic review and meta-analysis
by: Shan-shan Lu, et al.
Published: (2024-12-01)